MOREPENLAB · NSE Healthcare Large Cap

Morepen Laboratories Limited

MOREPENLAB  ·  National Stock Exchange of India

MOREPENLAB is currently trading at ₹116, 44.3% above its 50-day moving average. The Kasauti methodology audit finds 8 of 8 structural parameters confirmed, placing this instrument in the Passes All Criteria category.

Data Execution Timestamp: 11 September 2026 · NSE Closing Bell
Overall Verdict
कसौटी पर खरा उतरा
Passes All Criteria
Minervini SEPA 8 / 8
Weinstein Stage Stage 2 — Advance
Base Advance Top Decline
52-Week Price History — Weekly
₹116 Snapshot · NSE Closing Bell · 11 Sep 2026
₹32 ₹55 ₹77 ₹99 ₹122 Jul '25 Oct '25 Jan '26 Apr '26 Jul '26 52W H ₹118
Weekly close 50 DMA 200 DMA 52W high

Minervini SEPA — 8 Parameter Audit

Parameter Result Data
Price above 150 & 200 DMA
Minervini SEPA · Criterion 1
PASS Price ₹116 · 150 DMA ₹56 · 200 DMA ₹52
150 DMA above 200 DMA
Minervini SEPA · Criterion 2
PASS 150 DMA ₹56 vs 200 DMA ₹52 (+7.8%)
200 DMA trending up ≥ 1 month
Minervini SEPA · Criterion 3
PASS 200 DMA slope: +12.66% over 4 weeks
50 DMA above 150 & 200 DMA
Minervini SEPA · Criterion 4
PASS 50 DMA ₹80 · 150 DMA ₹56 · 200 DMA ₹52
Price above 50 DMA
Minervini SEPA · Criterion 5
PASS Price ₹116 · 50 DMA ₹80 (+44.3%)
Price within 25% of 52-week high
Minervini SEPA · Criterion 6
PASS ₹116 vs 52W high ₹123 (-5.5%)
Price ≥ 30% above 52-week low
Minervini SEPA · Criterion 7
PASS ₹116 vs 52W low ₹33 (+250.3%)
RS Rating ≥ 70
Minervini SEPA · Criterion 8
PASS RS Rating: 98 (threshold: ≥70)

Weinstein Stage Analysis

Stage 1
Base
Stage 2
Advance
Stage 3
Top
Stage 4
Decline

MOREPENLAB.NS is in Weinstein Stage 2 — the advancing phase. The 200-day moving average is trending upward, price is holding above all key moving averages, and the structure reflects institutional accumulation. This is the only stage where position traders should hold capital deployed in this instrument.

Relative Strength Rating

98 Stronger than 98% of the NSE universe
↑ Improving over 13 weeks

Structural Analysis

Morepen Laboratories Limited is currently trading 44.3% above its 50-day moving average, with Weinstein Stage 2 confirmed by the moving average hierarchy.

The Minervini SEPA audit finds 8 of 8 parameters confirmed. All criteria are satisfied.

Sanjaya's Reading

The Witness Speaks

Mitra, main dekh raha hoon Morepen Laboratories Limited ko — 8 criteria poore hain aath mein se.

Weinstein Stage 2 mein hai yeh instrument. कसौटी पर खरा उतरा.

This is a static snapshot

This audit was generated from NSE closing data on 11 September 2026. Run a live audit with real-time data, animated criteria reveals, and Sanjaya's full narration.

Run a Live Audit — Free →

Free tier includes Nifty 50 stocks · Pro unlocks full NSE universe

Frequently Asked Questions

Does MOREPENLAB pass the Minervini SEPA criteria?

MOREPENLAB (Morepen Laboratories Limited) currently meets 8 of 8 Minervini SEPA parameters. MOREPENLAB currently meets 8 of 8 Minervini SEPA parameters. All eight criteria are confirmed, placing this in the highest conviction tier.

What is the Weinstein Stage Analysis for MOREPENLAB?

MOREPENLAB is currently in Weinstein Stage 2. MOREPENLAB.NS is in Weinstein Stage 2 — the advancing phase. The 200-day moving average is trending upward, price is holding above all key moving averages, and the structure reflects institutional accumulation. This is the only stage where position traders should hold capital deployed in this instrument.

Is MOREPENLAB structurally aligned for position trading?

The Kasauti verdict for MOREPENLAB is कसौटी पर खरा उतरा (Passes All Criteria). The Kasauti verdict for MOREPENLAB.NS is कसौटी पर खरा उतरा — Passes All Criteria. With 8 of 8 criteria met, the stock satisfies all Minervini SEPA parameters in full. This is a structural methodology assessment only — not a recommendation to deploy or exit capital. This is a structural methodology assessment only — not a recommendation to deploy or exit capital.

Methodology Assessment Disclaimer: This page presents a systematic structural audit of MOREPENLAB against methodology parameters derived from the published works of Mark Minervini and Stan Weinstein. All data is sourced from NSE end-of-day prices. This content is for educational and analytical purposes only. Kasauti™ does not provide investment advice, stock recommendations, or capital deployment directives. Always conduct independent research and consult a SEBI-registered investment adviser before making any financial decisions.